Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose Tolerance
Open accessThe DOI matches its Crossref record; 34 of the 35 references it cites were found in a registry or an index.
Abstract
To characterize the defects in β-cell function in subjects with impaired fasting glucose (IFG) and compare the results to impaired glucose tolerance (IGT) and normal glucose tolerance (NGT) subjects, β-cell glucose sensitivity and rate sensitivity during the oral glucose tolerance test were measured with the model by Mari in 172 Mexican Americans. A subgroup (n = 70) received a 2-h hyperglycemic clamp (+125 mg/dL), and first- and second-phase insulin secretion were quantitated. Compared with NGT, subjects with IFG and IGT manifested a decrease in β-cell glucose sensitivity; IFG subjects, but not IGT subjects, had decreased β-cell rate sensitivity. In IFG subjects, the defect in β-cell glucose sensitivity was time dependent, began to improve after 60 min, and was comparable to NGT after 90 min. The incremental area under the plasma C-peptide concentration curve during the first 12 min of the hyperglycemic clamp (ΔC-pep[AUC]0–12) was inversely related with the increase in FPG concentration (r = −36, r = 0.001), whereas ΔC-pep[AUC]15–120 positively correlated with FPG concentration (r = 0.29, r < 0.05). When adjusted for the prevailing level of insulin resistance, first-phase insulin secretion was markedly decreased in both IFG and IGT, whereas second-phase insulin secretion was decreased only in IGT. These results demonstrate distinct defects in β-cell function in IFG and IGT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“These results demonstrate a definite beta-cell defect in IFG and IGT.[21]”
From Postprandial Reactive Hypoglycemia (2019) · cites this paper as [21]
In the citing paper
“β-cell dysfunction is present both in people with isolated IFG and isolated IGT. IFG people have severely impaired early insulin response during OGTT but their insulin secretion improves during the second phase of the OGTT. In contrast, IGT people present with impaired early and late phase insulin secretion.38,39,50”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [50]
In the citing paper
“These findings suggest distinct pathophysiological mechanisms of isolated IFG and isolated IGT although the clinical relevance of these observations requires further clarification.”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [50]
In the citing paper
“IFG is characterized primarily by impaired hepatic insulin sensitivity and a decrease in the first-phase insulin response”
From The Vasculature in Prediabetes (2018) · cites this paper as [13]
In the citing paper
“IGT is characterized by impaired muscle insulin sensitivity as well as early and late phase insulin responses.”
From The Vasculature in Prediabetes (2018) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,338
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 2×
“The glucose infusion rate divided by the mean plasma insulin concentration during the hyperglycemic clamp (0–120), an index of insulin sensitivity (26), was markedly reduced by 54% in subjects with IGT (P , 0.”
BackgroundMethodSelf-citationReport of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Writing committee, Unwin, N., Shaw, J., Zimmet, P., & Alberti, K. G. M. M. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00835.x · Cited by 1,108
Abdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744
Self-citationGerstein, H. C., Santaguida, P., Raina, P., Morrison, K. M., Balion, C., Hunt, D., Yazdi, H., & Booker, L. (2007) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2007.05.004 · Cited by 575
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Mari, A., & DeFronzo, R. A. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1133 · Cited by 540 · cited 5×
“b-Cell glucose sensitivity, rate sensitivity, and the potentiation factor were calculated with the model by Mari (12,22).”
MethodSelf-citationAbdul-Ghani, M. A., Jenkinson, C. P., Richardson, D. K., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes · doi:10.2337/db05-1200 · Cited by 500 · cited 2×
“This can be explained by 1) the time-related improvement in b-cell glucose sensitivity during the 60–120 min time period; 2) the increase in potentiation factor (Table 2); and 3) normal to near-normal muscle insulin sensitivity (9).”
BackgroundSelf-citationThe Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus
Garvey, W. T., Olefsky, J. M., Griffin, J., Hamman, R. F., & Kolterman, O. G. (1985) · Diabetes · doi:10.2337/diab.34.3.222 · Cited by 488 · cited 1×
“Conversely, improving glycemic control in type 2 diabetic subjects with insulin therapy improves b-cell function (27), and experimental studies in animals (28–30) have reported that a small rise (16 mg/dL) in FPG concentration is associated with a marked inhibition of glucose-stimulated insulin secretion, whereas corr…”
BackgroundEffect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats.
Rossetti, L., Shulman, G. I., Zawalich, W., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113157 · Cited by 330 · cited 1×
“Conversely, improving glycemic control in type 2 diabetic subjects with insulin therapy improves b-cell function (27), and experimental studies in animals (28–30) have reported that a small rise (16 mg/dL) in FPG concentration is associated with a marked inhibition of glucose-stimulated insulin secretion, whereas corr…”
BackgroundSelf-citationShaw, J. E., Zimmet, P. Z., de Courten, M., Dowse, G. K., Chitson, P., Gareeboo, H., Hemraj, F., Fareed, D., Tuomilehto, J., & Alberti, K. G. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.399 · Cited by 329
Meyer, C., Pimenta, W., Woerle, H. J., Van Haeften, T., Szoke, E., Mitrakou, A., & Gerich, J. (2006) · Diabetes Care · doi:10.2337/dc06-0438 · Cited by 308 · cited 2×
“Studies with the hyperglycemic clamp have reported a marked decrease in both first- and second-phase insulin secretion in IGT subjects (15,16,23).”
ResultWeyer, C., Bogardus, C., & Pratley, R. E. (1999) · Diabetes · doi:10.2337/diabetes.48.11.2197 · Cited by 292 · cited 4×
“Similarly, studies with the intravenous glucose tolerance test have demonstrated impaired acute insulin response in IGT (14,17,19,20).”
BackgroundResultInfluentialAssessing Insulin Secretion by Modeling in Multiple-Meal Tests
Mari, A., Tura, A., Gastaldelli, A., & Ferrannini, E. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s221 · Cited by 248 · cited 7×
“b-Cell glucose sensitivity, rate sensitivity, and the potentiation factor were calculated with the model by Mari (12,22).”
BackgroundMethodSelf-citationHanefeld, M., Koehler, C., Fuecker, K., Henkel, E., Schaper, F., & Temelkova-Kurktschiev, T. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.868 · Cited by 238
Gabir, M. M., Hanson, R. L., Dabelea, D., Imperatore, G., Roumain, J., Bennett, P. H., & Knowler, W. C. (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1113 · Cited by 211
Luzi, L., & DeFronzo, R. A. (1989) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1989.257.2.e241 · Cited by 186 · cited 1×
“OGTT or a meal (31), the impairment in early phase insulin secretion in subjects with IFG would be expected to result in less inhibition of endogenous glucose production, and this would contribute to the excessive rise in plasma glucose concentration during the first 60 min of the OGTT in IFG.”
BackgroundSelf-citationFesta, A., D’Agostino, R., Hanley, A. J. G., Karter, A. J., Saad, M. F., & Haffner, S. M. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1549 · Cited by 180 · cited 3×
“Similarly, studies with the intravenous glucose tolerance test have demonstrated impaired acute insulin response in IGT (14,17,19,20).”
BackgroundResultPathophysiology of prediabetes
Abdul-Ghani, M. A., & DeFronzo, R. A. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0032-7 · Cited by 177
Self-citationLeahy, J. L., Bonner-Weir, S., & Weir, G. C. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113470 · Cited by 171
Impaired fasting glucose or impaired glucose tolerance
Shaw, J. E., Zimmet, P., de Courten, M., Gk, D., Chitson, P., Gareeboo, H., Hemraj, F., Fareed, D., Tuomilehto, J., & Kgmm., A. (1999) · STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) · Cited by 169
Vegt, F. D., Dekker, J. M., Stehouwer, C. D. A., Nijpels, G., Bouter, L. M., & Heine, R. J. (1998) · Diabetes Care · doi:10.2337/diacare.21.10.1686 · Cited by 153
Ferrannini, E., Gastaldelli, A., Miyazaki, Y., Matsuda, M., Pettiti, M., Natali, A., Mari, A., & DeFronzo, R. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1169-6 · Cited by 133 · cited 2×
“, impaired b-cell glucose sensitivity for the entire duration of 2-h oral glucose stimulus (13,22).”
BackgroundSelf-citationLoss of beta cell function as fasting glucose increases in the non-diabetic range
Godsland, I. F., Jeffs, J. A. R., & Johnston, D. G. (2004) · Diabetologia · doi:10.1007/s00125-004-1454-z · Cited by 131 · cited 4×
“Similarly, studies with the intravenous glucose tolerance test have demonstrated impaired acute insulin response in IGT (14,17,19,20).”
BackgroundResultInfluentialAbdul-Ghani, M. A., Matsuda, M., Jani, R., Jenkinson, C. P., Coletta, D. K., Kaku, K., & DeFronzo, R. A. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00674.2007 · Cited by 91 · cited 1×
“Previous studies have reported that a small rise in the plasma glucose concentration has a detrimental effect on first-phase insulin secretion (14,17,19,20,25).”
BackgroundSelf-citationOsei, K., Gaillard, T., & Schuster, D. P. (1997) · Diabetes Care · doi:10.2337/diacare.20.3.396 · Cited by 73
Disturbances in β-Cell Function in Impaired Fasting Glycemia
van Haeften, T. W., Pimenta, W., Mitrakou, A., Korytkowski, M., Jenssen, T., Yki-Jarvinen, H., & Gerich, J. E. (2002) · Diabetes · doi:10.2337/diabetes.51.2007.s265 · Cited by 70
Who are more insulin resistant, people with IFG or people with IGT?
Wasada, T., Kuroki, H., Katsumori, K., Arii, H., Sato, A., Aoki, K., Jimba, S., & Hanai, G. (2004) · Diabetologia · doi:10.1007/s00125-004-1339-1 · Cited by 55 · cited 3×
“Similarly, studies with the intravenous glucose tolerance test have demonstrated impaired acute insulin response in IGT (14,17,19,20).”
BackgroundResultAbdul‐Ghani, M. A., Sabbah, M., Kher, J., Minuchin, O., Vardi, P., & Raz, I. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.595 · Cited by 47
Self-citationEhrmann, D. A., Breda, E., Cavaghan, M. K., Bajramovic, S., Imperial, J., TOFFOLO, G. M., Cobelli, C., & Polonsky, K. S. (2002) · Diabetologia · doi:10.1007/s00125-002-0776-y · Cited by 45 · cited 1×
“Similarly, studies with the graded intravenous glucose infusion technique have demonstrated impaired ability of IGT subjects to respond to a glucose stimulus (24).”
BackgroundPredicting the 20‐year diabetes incidence rate
Dankner, R., Abdul‐Ghani, M. A., Gerber, Y., Chetrit, A., Wainstein, J., & Raz, I. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.728 · Cited by 42
Self-citationAbdul‐Ghani, M. A., Matsuda, M., Sabbah, M., Jenkinson, C. P., Richardson, D. K., Kaku, K., & DeFronzo, R. A. (2007) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2007.02.004 · Cited by 40 · cited 1×
“Because previous studies have demonstrated that the contribution of b-cell dysfunction to the deterioration in glucose tolerance could be ethnic dependent (32), validation of the results of the current study in other ethnic groups will help generalize the results.”
ResultSelf-citationAcute hyperglycemia alters the ability of the normal β-cell to sense and respond to glucose
Meyer, J., Sturis, J., Katschinski, M., Arnold, R., Göke, B., & Byrne, M. M. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00427.2001 · Cited by 25
(2002) · PubMed · Cited by 17
Cited by
Prediabetes: a high-risk state for diabetes development
Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60283-9 · Cited by 2,958
Diabetes mellitus statistics on prevalence and mortality: facts and fallacies
Zimmet, P., Alberti, K. G., Magliano, D. J., & Bennett, P. H. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.105 · Cited by 785
Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
Self-citationMetabolic Effects of Bariatric Surgery in Patients With Moderate Obesity and Type 2 Diabetes
Kashyap, S. R., Bhatt, D. L., Wolski, K., Watanabe, R. M., Abdul-Ghani, M., Abood, B., Pothier, C. E., Brethauer, S., Nissen, S., Gupta, M., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1596 · Cited by 286
Self-citationKe, C., Narayan, K. M. V., Chan, J. C. N., Jha, P., & Shah, B. R. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00669-4 · Cited by 239
Metadata
- Authors
- Kanat, M., Mari, A., Norton, L., Winnier, D., DeFronzo, R. A., Jenkinson, C., & Abdul-Ghani, M. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, Texas
- Corresponding author
- Abdul-Ghani, Muhammad A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2012-01-17
- Volume
- 61
- Issue
- 2
- Pages
- 447-453
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3266412
- OpenAlex
- W2106830005
- Cited by
- 122
- References
- 35
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 3 · 2023: 6 · 2022: 6 · 2021: 8 · 2020: 13 · 2019: 9 · 2018: 13 · 2017: 6 · 2016: 12 · 2015: 6 · 2014: 14 · 2013: 7 · 2012: 5
- FWCI
- 10.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK079195)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- beta-cell function, impaired fasting glucose, impaired glucose tolerance, beta-cell glucose sensitivity, first-phase insulin secretion, second-phase insulin secretion, C-peptide, hyperglycemic clamp, oral glucose tolerance test, insulin resistance, prediabetes, Mexican Americans
- MeSH terms
- Adult, Blood Glucose, Fasting, Female, Glucose Tolerance Test, Humans, Insulin Resistance, Male, Middle Aged, Glucose Intolerance, Area Under Curve, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.